Objective To investigate the efficacy of darbepoetin alfa for the treatment of anemia and its effect on hemoglobin variation in hemodialysis patients.Methods A total of 38 stable hemodialysis patients treated in Hefei Jin'nan Kidney Disease Specialized Hospital from August 2022 to September 2023 were se-lected and randomly divided into two groups,observation group(n=19;2 dropped out)received darbepoetin alfa treatment,and control group(n=19)received conventional short-acting erythropoiesis stimulating agent treatment.The study consisted of a correction phase and a maintenance phase,with assays of hemoglobin and biochemical indicators monthly,and iron metabolism indicators at 0 and 5th months.Independent samples t-test was used to compare hemoglobin levels before and after treatment between the two groups.Paired t-test was used for before-after self-control comparisons in each group.Repeated measures analysis was performed to examine the trend of hemoglobin change in both groups over time.Chi-square test was used for adverse event analysis.Results There was no significant difference in pretreatment hemoglobin level between the two groups(t=0.174,P=0.863).Post-treatment hemoglobin level also had no significant difference(t=0.809,P=0.425).No significant differences in adverse events(heart failure events,P=1.000;fistula occlusion,P=1.000)were found between the two groups.During the correction phase,the observation group showed a more pronounced and stable hemoglobin increase(F=3.624,P=0.034).Conclusion Darbepoetin alfa has the safety and efficacy comparable to those of short-acting erythropoiesis stimulating agents,and can maintain he-moglobin at a stable increase level with less variability.
维普
万方数据